Evidence map›Paper›PMID 27197250›Full record

ReviewCancer research2016

The Role of Cholesterol in Cancer.

Omer F Kuzu, Mohammad A Noory, Gavin P Robertson

Abstract readReview
In one paragraph

Review in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 426 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
426citing papers in PubMed, 3 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

426 citing papers in PubMed, 3 syntheses or guidelines pooled it, 716 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. METTL16-mediated mJournal of experimental & clinical cancer research : CR · 2026
    Article
  18. Review
  19. Article
  20. Review

366 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Omer F KuzuDepartment of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Mohammad A NooryDepartment of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Gavin P RobertsonDepartment of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Department of Pathology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Department of Dermatology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Department of Surgery, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Penn State Hershey Melanoma Center, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Penn State Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. The Foreman Foundation for Melanoma Research, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. gprobertson@psu.edu.
Pennsylvania State University · US

Funding

Targeted Chemoprevention for MelanomaR01CA136667 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI ROBERTSON, GAVIN P. · 2010 to 2014
$2.1M
Akt3 Signaling as a Therapeutic TargetR01CA127892 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI ROBERTSON, GAVIN P. · 2008 to 2012
$1.5M
Synergistically Acting Targeted Therapeutics for MelanomaR01CA138634 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI ROBERTSON, GAVIN P. · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA127892NCI NIH HHS R01 CA136667NCI NIH HHS R01 CA138634
6 · The paper itself

Abstract

The roles played by cholesterol in cancer development and the potential of therapeutically targeting cholesterol homeostasis is a controversial area in the cancer community. Several epidemiologic studies report an association between cancer and serum cholesterol levels or statin use, while others suggest that there is not one. Furthermore, the Cancer Genome Atlas (TCGA) project using next-generation sequencing has profiled the mutational status and expression levels of all the genes in diverse cancers, including those involved in cholesterol metabolism, providing correlative support for a role of the cholesterol pathway in cancer development. Finally, preclinical studies tend to more consistently support the role of cholesterol in cancer, with several demonstrating that cholesterol homeostasis genes can modulate development. Because of space limitations, this review provides selected examples of the epidemiologic, TCGA, and preclinical data, focusing on alterations in cholesterol homeostasis and its consequent effect on patient survival. In melanoma, this focused analysis demonstrated that enhanced expression of cholesterol synthesis genes was associated with decreased patient survival. Collectively, the studies in melanoma and other cancer types suggested a potential role of disrupted cholesterol homeostasis in cancer development but additional studies are needed to link population-based epidemiological data, the TCGA database results, and preclinical mechanistic evidence to concretely resolve this controversy. Cancer Res; 76(8); 2063-70. ©2016 AACR.

Indexed as

AnimalsCholesterolHumansNeoplasmsRisk FactorsCholesterol

Identifiers

PMID27197250
PMCPMC5813477
OpenAlexW2318531023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.